摘要
目的:探讨普罗布考联合阿托伐他汀、阿司匹林治疗2型糖尿病(T2DM)合并脑梗死(CI)患者的效果。方法:选择厦门大学附属第一医院杏林分院2020年3月-2021年8月收治的192例T2DM合并CI患者为研究对象。按照随机数字表法分为对照组(96例)及观察组(96例),所有患者均给予常规治疗,对照组在此基础上联合阿司匹林(100 mg/次,1次/d)和阿托伐他汀(20 mg/次,1次/d)(AS治疗法)治疗,观察组在对照组基础上增加普罗布考(250 mg/次,2次/d)(PAS治疗法);观察治疗后两组的治疗效果、神经功能与斑块状况、血糖水平、脑血管功能及不良反应。结果:治疗后,观察组治疗总有效率(90.63%vs 79.17%)明显高于对照组(P<0.05);观察组NIHSS评分[(8.96±2.50)、(10.25±3.07)分]、斑块面积[(16.37±2.54)、(17.90±2.27)cm~2]、斑块数量[(1.56±0.37)、(1.70±0.34)个]及基质金属蛋白酶-9(MMP-9)[(65.49±20.11)、(72.44±22.65)ng/L]明显小于对照组(P<0.05);观察组糖化血红蛋白(HbA1c)[(8.41±0.91)%、(9.02±0.54)%]、空腹血糖(FPG)[(5.93±0.84)、(6.31±0.90)mmol/L]、餐后2 h血糖(2 h PG)[(9.12±2.70)、(10.10±3.04)mmol/L]水平均低于对照组(P<0.05);观察组血管内皮生长因子(VEGF)[(451.40±36.88)、(419.88±38.09)ng/L]水平明显高于对照组,血管紧张素-Ⅱ(Ang-Ⅱ)[(56.44±17.79)、(62.55±17.58)μg/L]、同型半胱氨酸(Hcy)[(49.44±7.70)、(52.50±8.91)μmol/L]、视黄醇结合蛋白4(RBP4)[(17.39±4.01)、(19.44±3.54)mg/L]均显著低于对照组(P<0.05);两组不良反应发生率比较差异无统计学意义(P=0.620)。结论:普罗布考联合阿托伐他汀、阿司匹林治疗T2DM合并CI可显著改善患者神经功能、血糖水平及脑血管功能,减少斑块数量及面积,从而提高治疗效果,且不会增加不良反应发生率。
Objective:To explore the effect of Probucol combined with Atorvastatin and Aspirin in the treatment of patients with type 2 diabetes mellitus(T2DM)complicated with cerebral infarction(CI).Method:A total of 192 patients with T2DM and CI who were admitted to Xinglin Branch of the First Affiliated Hospital of Xiamen University from March 2020 to August 2021 were selected as the subjects.The patients were divided into control group(96 cases)and observation group(96 cases)according to random number table method.All patients received routine treatment,on this basis,the control group was treated with Aspirin(100 mg/time,1 time/day)and Atorvastatin(20 mg/time,1 time/day)(AS therapy),the observation group was added Probucol(250 mg/time,2 times/d)(PAS treatment)on the basis of the control group.The therapeutic effect,neurological function and plaque status,blood glucose level,cerebrovascular function and adverse reactions of the two groups were observed.Result:After treatment,the total effective rate in the observation group(90.63%vs 79.17%)was significantly higher than that in the control group(P<0.05).The NIHSS score[(8.96±2.50),(10.25±3.07)points],plaque area[(16.37±2.54),(17.90±2.27)cm~2],plaque number[(1.56±0.37),(1.70±0.34)]and matrix metalloprotein-9(MMP-9)[(65.49±20.11),(72.44±22.65)ng/L]in the observation group were significantly lower than those in the control group(P<0.05).The levels of glycated hemoglobin(HbA1c)[(8.41±0.91)%,(9.02±0.54)%],fasting plasma glucose(FPG)[(5.93±0.84),(6.31±0.90)mmol/L]and 2-hour postprandial plasma glucose(2 h PG)[(9.12±2.70),(10.10±3.04)mmol/L]in the observation group were lower than those in the control group(P<0.05).The level of vascular endothelial growth factor(VEGF)[(451.40±36.88),(419.88±38.09)ng/L]in the observation group was significantly higher than that in the control group,and the levels of angiotensin-Ⅱ(Ang-Ⅱ)[(56.44±17.79),(62.55±17.58)μg/L],homocysteine(Hcy)[(49.44±7.70),(52.50±8.91)μmol/L],retinol binding protein 4(RBP4)[(17.39±4.01),(19.44�
作者
范丽萍
孙强
覃弘宇
FAN Liping;SUN Qiang;QIN Hongyu(Xinglin Branch of the First Affiliated Hospital of Xiamen University,Xiamen 361022,China;不详)
出处
《中外医学研究》
2022年第25期9-13,共5页
CHINESE AND FOREIGN MEDICAL RESEARCH
基金
福建省大学启航基金项目(2020QH1113)。
